Halachmi Sarel, Farhat Walid, Metcalfe Peter, Bagli Darius J, McLorie Gordon A, Khoury Antoine E
Division of Urology, Hospital for Sick Children, Toronto, Ontario, Canada.
J Urol. 2004 Mar;171(3):1287-90. doi: 10.1097/01.ju.0000111221.43756.a3.
Achieving urinary continence is a major goal in the treatment of patients with bladder exstrophy/epispadias, spinal dysraphism and other urological disorders. Endoscopic injection of bulking materials is an evolving, minimally invasive procedure that provides an attractive alternative to open bladder surgery to increase outlet resistance. We evaluated the efficacy of bladder outlet (bladder neck and diverting stoma) polydimethylsiloxane injection (BOMI) to achieve continence in children.
We retrospectively reviewed the continence status of 33 patients prior to and following BOMI for urinary incontinence. The variables evaluated as predictors of success were underlying disease, ambulatory status, voiding status, bladder capacity, type and time from previous bladder neck reconstruction, anticholinergic treatment, injection site, amount of polydimethylsiloxane used, detrusor leak point pressure and immediate or delayed clean intermittent catheterization. Improvement was considered a 2-fold increase in the dry interval or 4 hours between bladder emptying in patients on clean intermittent catheterization and a 2-fold decrease in the number of absorbent pads needed.
Between 1998 and 2002, 25 male and 8 female patients 4 to 19 years old (mean age 12.4 +/- 3.9) underwent 42 BOMIs for incontinence. Mean followup was 13 +/- 9 months (range 3 to 42). Incontinence was via the urethra in 28 cases and via a diverting stoma in the remaining 5. Of the 28 patients with leakage via the urethra none were cured, 12 (42%) were improved and 16 (58%) had no change in continence status. However, 3 of the 5 inpatients (60%) with leakage via a diverting stoma were cured. No perioperative complications were recorded. Injecting to a diverting stoma was the only factor found to be predictive of success. Extrusion of polydimethylsiloxane during the procedure was the only factor predictive of failure (3 of 3 cases or 100%). New onset dilatation of the collecting system was noted in 2 patients and all had improved continence following injection.
Injection to the bladder neck did not result in any cure and had a low improvement rate of 42%. BOMI is a good therapeutic option for patients with leakage from a diverting stoma. Although no perioperative complications were recorded, 2 patients had new dilatation of the upper tract on ultrasound. Hence, long-term followup is warranted.
实现尿失禁控制是膀胱外翻/尿道上裂、脊柱裂及其他泌尿系统疾病患者治疗的主要目标。内镜下注射填充材料是一种不断发展的微创治疗方法,为开放膀胱手术增加出口阻力提供了一种有吸引力的替代方案。我们评估了膀胱出口(膀胱颈和引流造口)聚二甲基硅氧烷注射(BOMI)对儿童实现尿失禁控制的疗效。
我们回顾性分析了33例患者在BOMI治疗尿失禁前后的尿失禁控制情况。评估作为成功预测指标的变量包括基础疾病、活动状态、排尿状态、膀胱容量、上次膀胱颈重建的类型和时间、抗胆碱能治疗、注射部位、聚二甲基硅氧烷用量、逼尿肌漏点压力以及即时或延迟清洁间歇性导尿。改善定义为接受清洁间歇性导尿的患者干燥间隔时间增加2倍或膀胱排空间隔4小时,以及所需吸收垫数量减少2倍。
1998年至2002年,25例男性和8例女性患者,年龄4至19岁(平均年龄12.4±3.9岁),因尿失禁接受了42次BOMI治疗。平均随访时间为13±9个月(范围3至42个月)。28例患者经尿道尿失禁,其余5例经引流造口尿失禁。28例经尿道漏尿患者无治愈者,12例(42%)有改善,16例(58%)尿失禁控制情况无变化。然而,5例经引流造口漏尿的住院患者中有3例(60%)治愈。未记录围手术期并发症。发现向引流造口注射是唯一预测成功的因素。手术过程中聚二甲基硅氧烷挤出是唯一预测失败的因素(3例中的3例,即100%)。2例患者出现新的集合系统扩张,注射后尿失禁均有改善。
向膀胱颈注射未导致任何治愈,改善率低,为42%。BOMI是引流造口漏尿患者的良好治疗选择。虽然未记录围手术期并发症,但2例患者超声检查发现上尿路有新的扩张。因此,需要长期随访。